Related Experiment Videos
[The heart and metabolic syndrome]
D Tschoepe1, P Roesen, W A Scherbaum
1Diabetes-Forschungsinstitut an der Heinrich-Heine-Universität Arbeitsgruppe Zelluläre Hämostase und Klinische Angiologie, Düsseldorf. tschoepe@uni-duesseldorf.de
Zeitschrift Fur Kardiologie
|June 4, 1999
Summary
Metabolic syndrome accelerates coronary artery disease through a prothrombotic state, increasing risks of heart attack. Comprehensive treatment beyond glucose control is vital for managing these complex cardiovascular risks.
Area of Science:
- Cardiovascular Medicine
- Endocrinology
- Hematology
Context:
- Metabolic syndrome, characterized by dyslipoproteinemia, hypertension, and obesity, significantly increases cardiovascular risk.
- Type-2 diabetes exacerbates this risk, contributing to accelerated coronary artery disease and specific cardiopathy.
- The underlying mechanisms involve a complex interplay of genetic susceptibility and metabolic dysregulation.
Purpose:
- To elucidate the pathophysiological mechanisms linking metabolic syndrome and type-2 diabetes to thrombotic complications.
- To understand the role of altered coagulation and platelet function in atherothrombosis within this patient group.
- To evaluate the effectiveness of current interventions and propose a multidimensional approach for secondary prevention.
Summary:
- Patients with metabolic syndrome exhibit a prothrombotic state with increased coagulation, diminished fibrinolysis, and heightened platelet reactivity (diabetic thrombocytopathy).
- These factors, alongside altered cardiac remodeling, contribute to atherothrombosis, myocardial infarction, and reduced efficacy of interventions like PTCA and CABG.
- Glucose control alone is insufficient; parenteral glucose-insulin-potassium infusion is crucial during myocardial infarction, followed by long-term multidimensional therapy.
Impact:
- Highlights the inadequacy of glucose management alone in mitigating cardiovascular events in metabolic syndrome.
- Emphasizes the need for a comprehensive, individualized secondary prevention strategy including antihypertensive, antidyslipoproteinemic, and antithrombotic therapies.
- Underscores the importance of early diagnostic measures for tailoring interventions and improving outcomes in high-risk patients.